<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7418</journal-id>
<journal-title><![CDATA[Revista Colombiana de Ciencias Químico - Farmacéuticas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. cienc. quim. farm.]]></abbrev-journal-title>
<issn>0034-7418</issn>
<publisher>
<publisher-name><![CDATA[Departamento de Farmácia, Facultad de Ciencias, Universidade Nacional da Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74182018000200233</article-id>
<article-id pub-id-type="doi">10.15446/rcciquifa.v47n2.73968</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Agentes dopaminérgicos centrales análogos N-aralquil metoxilados del 2-aminoindano]]></article-title>
<article-title xml:lang="en"><![CDATA[Central dopaminergic agents analogues of N-aralkyl methoxylated of 2-aminoindane]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suárez Bozo]]></surname>
<given-names><![CDATA[Geraldine]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sanguino Díaz]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lucena]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ocampo Hernández]]></surname>
<given-names><![CDATA[Miriam]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Villasmil]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Balza Jiménez]]></surname>
<given-names><![CDATA[Katherin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vera Sosa]]></surname>
<given-names><![CDATA[Mariagracia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Migliore]]></surname>
<given-names><![CDATA[Ligia Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Migliore de Ángel]]></surname>
<given-names><![CDATA[Biagina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Charris Charris]]></surname>
<given-names><![CDATA[Jaime]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Israel]]></surname>
<given-names><![CDATA[Anita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López D' Sola]]></surname>
<given-names><![CDATA[Simón]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Izquierdo]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caldera Luzardo]]></surname>
<given-names><![CDATA[José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ortega Fernández]]></surname>
<given-names><![CDATA[José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez Morán]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guio]]></surname>
<given-names><![CDATA[Jorge Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Zulia Facultad Experimental de Ciencias Departamento de Química]]></institution>
<addr-line><![CDATA[Maracaibo ]]></addr-line>
<country>Venezuela</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Central de Venezuela Facultad de Farmacia Laboratorio de Síntesis Orgánica]]></institution>
<addr-line><![CDATA[Caracas ]]></addr-line>
<country>Venezuela</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Central de Venezuela Facultad de Farmacia Laboratorio de Neuropéptidos]]></institution>
<addr-line><![CDATA[Caracas ]]></addr-line>
<country>Venezuela</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,University of Florida Department of Chemistry ]]></institution>
<addr-line><![CDATA[Gainesville Florida]]></addr-line>
<country>USA</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2018</year>
</pub-date>
<volume>47</volume>
<numero>2</numero>
<fpage>233</fpage>
<lpage>253</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74182018000200233&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74182018000200233&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74182018000200233&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La neurotransmisión dopaminérgica interviene en los mecanismos que involucran los procesos motores, cognoscitivos, conductuales y neurocrinos y su mal funcionamiento la involucra en los trastornos neurodegenerativos que afectan al sistema nervioso central (SNC), tales como en la enfermedad de Parkinson y la enfermedad de Huntington, entre otras. Con el propósito de encontrar una solución terapéutica a estas patologías, en publicaciones anteriores hemos reportado la síntesis, la evaluación farmacológica y el estudio teórico computacional de los compuestos análogos mono y dihidroxilados (sobre el anillo indano) del N-aralquil-2-aminoindano 4-8, análogos 4,7-dimetoxi-2-aminoindano-N-aralquil, bajo sus formas metoxiladas sobre el anillo bencénico del fragmento aralquil 9 y el derivado fenólico 10, así como también los análogos diclorados del N-aralquil-2-aminoindano 11 con actividades dopaminérgicas centrales. En el presente trabajo se sintetizaron los clorhidratos del 2-aminoindano- N-[2-(mono o dimetoxi)-fenil)-1-metil-etil] 12-15 y su evaluación farmacológica mostraron respuestas agonísticas como potenciales agentes antihuntington y antipárkinson.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Dopaminergic neurotransmission is implicated in mechanisms that involve motor, cognoscitive, conductual and neurocrine process, and its malfunction involucrates it in neurodegenerative disorders affecting central nervous system (CNS), like Parkinson's disease and Huntington's disease, among others. On the purpose of finding some therapeutic for these pathologies, in previous researches we have reported synthesis, pharmacological evaluation and theoretical computational study of compounds analogues mono or di hydroxilated (on indane ring) of N-aralkyl-2-aminoindane 4-8, analogues 4,7-dimethoxy-2-aminoindane-N-aralkyl, under its methoxylated forms on benzene ring of aralkyl fragment 9 and phenolic derivate 10, also dichlorade analogs of N-aralkyl-2-aminoindane 11 with central dopaminergic activities. In this work were synthesized hydrochlorides of 2-aminoindane-N-[(mono or di methoxy)-phenyl-1-methyl-ethyl] (12-15) and its pharmacologic evaluation showed agonistic responses as potential agents anti Huntington and/or anti Parkinson.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[enfermedad de Huntington]]></kwd>
<kwd lng="es"><![CDATA[enfermedad de Parkinson]]></kwd>
<kwd lng="es"><![CDATA[agonistas dopaminérgicos]]></kwd>
<kwd lng="es"><![CDATA[N-aralquil]]></kwd>
<kwd lng="es"><![CDATA[aminoindano]]></kwd>
<kwd lng="en"><![CDATA[Huntington's disease]]></kwd>
<kwd lng="en"><![CDATA[Parkinson's disease]]></kwd>
<kwd lng="en"><![CDATA[dopaminergic agonists]]></kwd>
<kwd lng="en"><![CDATA[N-aralkyl]]></kwd>
<kwd lng="en"><![CDATA[aminoindane]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montaño-Arias]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Bahena-Trujillo]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dopamina: síntesis, liberación y receptores en el sistema nervioso central]]></article-title>
<source><![CDATA[Rev. Biomed]]></source>
<year>2000</year>
<volume>11</volume>
<numero>39</numero>
<issue>39</issue>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sachar]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Zuk]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Gazawi]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ljubuncic]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dopamine toxicity involves mitochondrial complex I inhibition: Implications to dopamine-related neuropsychiatric disorders]]></article-title>
<source><![CDATA[Biochem. Pharm]]></source>
<year>2004</year>
<volume>67</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1965</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beaulieu]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Gainetdinov]]></surname>
<given-names><![CDATA[R.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The physiology, signaling, and pharmacology of dopamine receptors]]></article-title>
<source><![CDATA[Pharmacol. Rev]]></source>
<year>2011</year>
<volume>63</volume>
<page-range>182</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Neumeyer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Baldessarini]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent progress in development of dopamine receptor subtype-selective agents: Potential therapeutics for neurological and psychiatric disorders]]></article-title>
<source><![CDATA[Chem. Rev]]></source>
<year>2007</year>
<volume>1</volume>
<numero>28</numero>
<issue>28</issue>
<page-range>274</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rall]]></surname>
<given-names><![CDATA[T.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Nies]]></surname>
<given-names><![CDATA[A.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Goodman &amp; Gilman. Las bases farmacológicas de la terapéutica]]></source>
<year>1991</year>
<volume>8</volume>
<page-range>458-61</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neumeyer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Arana]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Ram]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Kula]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Baldessarini]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxy-apomorphine]]></article-title>
<source><![CDATA[J. Med. Chem]]></source>
<year>1982</year>
<volume>25</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>990</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brichta]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Greengard]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Flajolet]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in the pharmacological treatment of Parkinson's disease: Targeting neurotransmitter systems]]></article-title>
<source><![CDATA[Trends Neuro-sci]]></source>
<year>2013</year>
<volume>36</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>543</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gatto]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedad de Huntington]]></article-title>
<source><![CDATA[Rev. Neuropsiquiatr]]></source>
<year>2002</year>
<volume>65</volume>
<page-range>202</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Encinosa]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[huntington]]></surname>
<given-names><![CDATA[Corea de]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev. Cubana Genet. Human]]></source>
<year>2001</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ángel-Guío]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-Roca]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[B. Migliore de]]></given-names>
</name>
<name>
<surname><![CDATA[Israel]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Charris]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Caldera]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Conformational theoretical study of substituted and non-substituted N-aralkyl-2-aminoindans and its relation with dopaminergic activity]]></article-title>
<source><![CDATA[J. Mol. Struct. (Theochem)]]></source>
<year>2003</year>
<volume>636</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ángel Guío]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Charris]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Israel]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[B. Migliore de]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-Roca]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Michelena de Báez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Moronta]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Quintero]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil dopaminérgico del compuesto 2-aminoindano-N-aralquil sustituido]]></article-title>
<source><![CDATA[Arch. Venezol. Terap. Farmacol]]></source>
<year>2004</year>
<volume>23</volume>
<page-range>136</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andújar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Garibotto]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Migliore de Ángel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ángel-Guío]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Charris]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Enriz]]></surname>
<given-names><![CDATA[R.D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular recognition and binding mechanism of N-aralkyl substituted 2 aminoindans to the dopamine D2 receptor. A theoretical study]]></article-title>
<source><![CDATA[J. Argent. Chem. Soc]]></source>
<year>2006</year>
<volume>94</volume>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[na compilación en el diseño y evaluación farmacológica preliminar de nuevos compuestos con actividad dopaminérgica central]]></article-title>
<source><![CDATA[Invest. Clin]]></source>
<year>2008</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Andújar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Migliore d Ángel]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Charris]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Israel]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-Roca]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Visbal]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosales]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Suvire]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Enriz]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synthesis, dopaminergic profile and molecular dynamics calculations of N-Aralkyl substituted 2-aminoindans]]></article-title>
<source><![CDATA[Bioorg. Med. Chem]]></source>
<year>2008</year>
<volume>16</volume>
<page-range>3233</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[R.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Urdaneta]]></surname>
<given-names><![CDATA[N.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Porta]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[L.Ch.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosales]]></surname>
<given-names><![CDATA[C. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Espinoza]]></surname>
<given-names><![CDATA[G.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[L.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Balza]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Perdomo]]></surname>
<given-names><![CDATA[L.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Faría]]></surname>
<given-names><![CDATA[A.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Dabian]]></surname>
<given-names><![CDATA[A.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Zapata]]></surname>
<given-names><![CDATA[M.V.]]></given-names>
</name>
<name>
<surname><![CDATA[Linero]]></surname>
<given-names><![CDATA[A.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Acurero]]></surname>
<given-names><![CDATA[G.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Israel]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[M.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-Roca]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Migliore de Ángel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[S.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Charris]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novedosos agentes dopaminérgicos centrales derivados del 2-aminoindano- 4,7 disustituido atípico. Síntesis y perfil farmacológico central]]></article-title>
<source><![CDATA[Invest. Clin]]></source>
<year>2015</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>137</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[L.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Velásquez]]></surname>
<given-names><![CDATA[M.V.]]></given-names>
</name>
<name>
<surname><![CDATA[Caldera]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Vera]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[C.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[L.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Migliore de Ángel]]></surname>
<given-names><![CDATA[B. C]]></given-names>
</name>
<name>
<surname><![CDATA[Charris]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Israel]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[S.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Izquierdo]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[J.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síntesis y evaluación farmacológica de los novedosos agentes dopaminérgicos centrales análogos del N-dicloroaralquil-2-aminoindano]]></article-title>
<source><![CDATA[Rev. Fac. Farm., UCV]]></source>
<year>2018</year>
<volume>81</volume>
<numero>1, 2</numero>
<issue>1, 2</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Charris]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Duerto]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[N-aralkyl substitution of 2-aminoindans. Synthesis and their inotropic and chronotropic activity in isolated guinea pig atria]]></article-title>
<source><![CDATA[Arzneimittel-Forsch]]></source>
<year>1997</year>
<volume>47</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1208</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vera]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Síntesis de análogos del 2-aminoindano con posible actividad farmacológica]]></source>
<year>1984</year>
<page-range>126</page-range><publisher-name><![CDATA[Universidad Central de Venezuela]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[L.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Balza]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Perdomo]]></surname>
<given-names><![CDATA[L.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Dabian]]></surname>
<given-names><![CDATA[A.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Faría]]></surname>
<given-names><![CDATA[A.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Linero]]></surname>
<given-names><![CDATA[A.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Migliore de Ángel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Suárez-Roca]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Charris]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Israel]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez de Bracho]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ángel]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síntesis y evaluación farmacológica preliminar de nuevos compuestos quinolínicos con actividad anticorea de huntington]]></article-title>
<source><![CDATA[Rev. Fac. Farm., UCV]]></source>
<year>2015</year>
<volume>78</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>94</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francis-Turner]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bergado]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Bergado]]></surname>
<given-names><![CDATA[R.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos del factor de crecimiento nervioso (ngF) sobre la conducta en un modelo experimental de corea de huntington en ratas]]></article-title>
<source><![CDATA[Rev. Tumbaga]]></source>
<year>2006</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>55</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Snedecor]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Cochran]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Statistical methods]]></source>
<year>1982</year>
<volume>7</volume>
<page-range>534</page-range><publisher-name><![CDATA[Iowa State University Press, Amer. Ser. Printing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rollema]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[5HT1a receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex]]></article-title>
<source><![CDATA[Biol. Psychiatry]]></source>
<year>2000</year>
<volume>48</volume>
<page-range>229</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costall]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Marsden]]></surname>
<given-names><![CDATA[C.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Naylor]]></surname>
<given-names><![CDATA[R.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Pycock]]></surname>
<given-names><![CDATA[C.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stereotyped behavior patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nucleus]]></article-title>
<source><![CDATA[Brain Res]]></source>
<year>1977</year>
<volume>123</volume>
<page-range>89</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costall]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Naylor]]></surname>
<given-names><![CDATA[R.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[J.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[T.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differentiation of the dopamine mechanisms mediating stereotyped behavior and hyperactivity in the nucleus accumbens and caudate-putamen]]></article-title>
<source><![CDATA[J. Pharm. Pharmacol]]></source>
<year>1977</year>
<volume>29</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>337</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kapur]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Daskalakis]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Remington]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Zipursky]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine]]></article-title>
<source><![CDATA[Am. J. Psychiatry]]></source>
<year>2001</year>
<volume>158</volume>
<page-range>311</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bardin]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Kleven]]></surname>
<given-names><![CDATA[M.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Barret-Grévoz]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Depoortere]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Newman-Tancredi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antipsychotic-like vs. cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2006</year>
<volume>31</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1869</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luquin]]></surname>
<given-names><![CDATA[M.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modelos experimentales de enfermedad de Parkinson]]></article-title>
<source><![CDATA[Rev. Neurol]]></source>
<year>2000</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>60</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
